Olema Pharma climbs on collaboration agreement with Bayer

Bayer AG

26/05/2026 12:42

** Shares of Olema Pharmaceuticals OLMA.O rise 1.5% to $13.89 premarket 
** The drug developer says it signed a clinical trial and supply agreement with German drugmaker Bayer AG BAYGn.DE for its experimental drug OP-3136
** OP-3136 being developed in combination with Bayer's darolutamide to treat patients with a type of prostate cancer - OLMA 
** Under the terms of the agreement, Bayer will supply darolutamide for use in an early to mid-stage study and Olema will lead the conduct of the study
** Up to last close, OLMA down 45.3% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))